Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD38 Double Nickase Plasmid (h): sc-401117-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD38 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CD38 Double Nickase Plasmid (h) and CD38 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CD38. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD38 Antibody (H-11): sc-374650
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD38 Double Nickase Plasmid (h) | sc-401117-NIC | 20 µg | $410.00 | |||
CD38 Double Nickase Plasmid (h2) | sc-401117-NIC-2 | 20 µg | $410.00 |
Human CD38 encodes a multifunctional ectoenzyme and receptor that regulates NAD⁺ metabolism by catalyzing the formation and hydrolysis of cyclic ADP-ribose and related metabolites, thereby shaping intracellular Ca²⁺ mobilization. Through these activities, CD38 influences signal transduction linked to lymphocyte activation, differentiation, and immune synapse function, and it can modulate cellular redox state and metabolic fitness via NAD⁺ availability. CD38-dependent pathways intersect with inflammatory signaling and immune cell trafficking, making CD38 a frequent focus in studies of immunometabolism, hematologic malignancies, and chronic inflammatory disease mechanisms. Its expression and enzymatic output are also used to contextualize cell state changes in tumor microenvironments and during immune exhaustion or activation.
CD38 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CD38 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CD38. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CD38 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CD38-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.